A pharmaceutical monitoring system to assess the quality of antituberculosis drug products used in Mauritania.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
06
2022
accepted:
07
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
The quality of drug products may be affected from manufacture to dispensing, particularly at high temperature and humidity as in Mauritania. This country is not included in the World Health Organization reports on poor quality products due to the lack of a qualified laboratory and monitoring system. Ensuring the quality of medicine is even more relevant in the case of diseases such as Tuberculosis, due to its high prevalence, complex treatment and continuous bacterial resistance. The aim was to develop a monitoring system to assess the quality of antituberculosis drugs products, by the substandard detection based on European and United States Pharmacopeial recommendations regarding quality control. In addition to studying the influence of accelerated storage conditions (40 ± 2°C/75 ± 5% relative humidity) on their qualities and comparing the dissolution profiles to contrast the quality. 18 antituberculosis drug products were taken from Europe and Mauritania, and quality was studied through visual inspection and according to the compliance of the mass uniformity, uniformity of dosage units, dissolution, disintegration and friability pharmacopeial tests. Furthermore, a dissolution profile comparison was carried out to examine quality. A stability study was conducted to assess the influence of climatic conditions on the content and the dissolved amount of the active pharmaceutical ingredients, which were determined by an ultra-performance liquid chromatography system. As result, 69.3% of 13 Mauritanian formulations had a substandard quality mainly due to non-compliance with the test for friability or content uniformity of these medicines. All European drug products complied with pharmacopeia specifications. In addition, storage conditions affected the dissolution rate of ethambutol and the uniformity of the 4 antituberculosis combination drug products.
Identifiants
pubmed: 36928659
doi: 10.1371/journal.pone.0282023
pii: PONE-D-22-16336
pmc: PMC10019615
doi:
Substances chimiques
Antitubercular Agents
0
Pharmaceutical Preparations
0
Tablets
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282023Informations de copyright
Copyright: © 2023 Cáceres-Pérez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no Competing interests exist.
Références
Int J Pharm. 2002 Oct 1;245(1-2):37-44
pubmed: 12270240
Int J Tuberc Lung Dis. 2004 Sep;8(9):1073-80
pubmed: 15455591
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):221-5
pubmed: 20070293
Pharmacy (Basel). 2020 Mar 19;8(1):
pubmed: 32204459
Pharm Dev Technol. 2005;10(4):517-24
pubmed: 16370181
Lancet. 2001 Jun 16;357(9272):1933-6
pubmed: 11425415
Int J Tuberc Lung Dis. 2005 Nov;9(11):1266-72
pubmed: 16333936
Drug Dev Ind Pharm. 2020 Feb;46(2):309-317
pubmed: 31944867
Int J Tuberc Lung Dis. 2005 Jun;9(6):654-60
pubmed: 15971393
J Pharm Sci. 2018 Jun;107(6):1667-1679
pubmed: 29462633
Trop Med Int Health. 2013 Sep;18(9):1141-1144
pubmed: 23937703
Front Pharmacol. 2019 Aug 14;10:881
pubmed: 31474853
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S347-50; discussion S351-2
pubmed: 10593716
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1161-1168
pubmed: 28911362
J Pharm Biomed Anal. 2015 Jan;102:9-16
pubmed: 25218029
PLoS One. 2014 Jul 08;9(7):e102047
pubmed: 25004128
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35981806
Int J Tuberc Lung Dis. 2004 Sep;8(9):1081-8
pubmed: 15455592
JAMA Netw Open. 2018 Aug 3;1(4):e181662
pubmed: 30646106
Int J Tuberc Lung Dis. 2013 Mar;17(3):308-11
pubmed: 23321423